Abstract 125P
Background
Immunotherapy is vital for melanoma treatment, with tumor vaccines showing promise. Previous studies suggest circadian rhythms may impact immune responses, yet their effect on tumor vaccine efficacy is unclear. To optimize vaccine outcomes, we investigated the differences in melanoma treatment efficacy when vaccines were administered at different times, aiming to find the optimal therapeutic window.
Methods
We compared the efficacy of a neoantigen tumor vaccine developed by our team when administered during the active phase (ZT21) versus the rest phase (ZT9) in C57BL/6 mice with B16-F10 melanoma (ZT refers to Zeitgeber Time, where ZT0 is the time of lights on, and ZT12 is lights off). IVIS imaging was used to track vaccine targeting of lymph nodes at different time points. Flow cytometry, immunohistochemistry, and RT-PCR were performed to assess changes in CD8+ and CD4+ T cells in the tumor microenvironment, lymph nodes, and spleen post-vaccination.
Results
In a melanoma model, vaccine administration during the rest phase (ZT9) showed better tumor inhibition compared to the active phase (ZT21). IVIS results indicated faster lymph node targeting at ZT9. Flow cytometry and immunohistochemistry revealed that ZT9 administration increased tumor-infiltrating CD8+ and CD4+ T cells, with a higher proportion of CD69+ T cells, leading to stronger anti-tumor immune responses.
Conclusions
Administering tumor vaccines during the rest phase, compared to the active phase, leads to faster lymph node targeting and stronger anti-tumor immune responses, resulting in better therapeutic outcomes. Thus, treatment timing should be considered in clinical immunotherapy, with vaccines administered during the rest phase for maximum clinical benefit.
Legal entity responsible for the study
West China Hospital, Sichuan University.
Funding
Sichuan Science and Technology Program.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract